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Rotator cuff injuries are a common source of shoulder pathology and result in an important decrease in quality of patient life.
Given the frequency of these injuries, as well as the relatively poor result of surgical intervention, it is not surprising that new
and innovative strategies like tissue engineering have become more appealing. Tissue-engineering strategies involve the use of
cells and/or bioactive factors to promote tendon regeneration via natural processes. The ability of numerous growth factors to
affect tendon healing has been extensively analyzed in vitro and in animal models, showing promising results. Platelet-rich plasma
(PRP) is a whole blood fraction which contains several growth factors. Controlled clinical studies using different autologous PRP
formulations have provided controversial results. However, favourable structural healing rates have been observed for surgical
repair of small and medium rotator cuff tears. Cell-based approaches have also been suggested to enhance tendon healing. Bone
marrow is a well known source of mesenchymal stem cells (MSCs). Recently, ex vivo human studies have isolated and cultured
distinct populations of MSCs from rotator cuff tendons, long head of the biceps tendon, subacromial bursa, and glenohumeral
synovia. Stem cells therapies represent a novel frontier in the management of rotator cuff disease that required further basic and
clinical research.
1. Introduction
Rotator cuff lesions represent the vast majority of shoulder
injuries in adult patients and are a common contributing
factor to shoulder pain and occupational disability.
The incidence of this condition is increasing along with
an aging population [1].Themanagement of rotator cuff tears
is complex and multifactorial. Operative treatment allows
primary repair to be performed either as an open or arthro-
scopic procedure.
Improvements in arthroscopic instrumentation and
suture anchor technology have allowed the development
of stronger constructs with multiple suture configurations,
allowing repair of large and massive tears through minimally
invasive means. However, although repair instrumentation
and techniques have improved, healing rates have not. A
high failure rate remains for large and massive rotator cuff
tears [2, 3].
A recent meta-analysis has shown that the development
and introduction of novel surgical techniques are not related
to an improvement of clinical and anatomical results over the
investigated period (1980–2012) [4].
To enhance tendon tissue regeneration, new biologi-
cal solutions including growth factors, platelet-rich plasma
(PRP), and stem cells are being investigated.
This reviewwill outline the current evidence for the novel
frontier in the management of rotator cuff disease including
growth factor and stem cell therapy.
2. Growth Factors
Growth factors are signal molecules involved in the control
of cell growth and differentiation and are active in different
phases of inflammation. They are produced by inflammatory
cells, platelets, and fibroblasts.
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 129515, 9 pages
http://dx.doi.org/10.1155/2014/129515
2 BioMed Research International
Rotator cuff healing occurs via a sequence of inflam-
mation, repair, and remodeling [21]. Several growth fac-
tors released in the repair phase act in both an autocrine
and paracrine fashion to promote cellular proliferation and
matrix deposition. These include basic fibroblast growth
factor (bFGF), bone morphogenetic proteins 12, 13, and 14
(BMP-12,13,14), vascular endothelial growth factor (VEGF),
platelet derived growth factor (PDGF-𝛽), transforming
growth factor-beta (TGF-𝛽), and insulin-like growth factor-1
(IGF-1) [22, 23].
Because rotator cuff healing results in reactive scar for-
mation rather than a histologically normal insertion site,
addition of these factors may enhance the repair-site biology.
PDGF is a basic protein composed of two subunits, an
A and a B chain, that exists in three main isoforms (PDGF-
AA, PDGF-BB, and PDGF-AB). These isoforms function
as chemotactic agents for inflammatory cells and help to
increase type I collagen synthesis and induce TGF-𝛽1 expres-
sion [22]. The homodimer PDGF-BB has been the subject
of most research because it stimulates both matrix synthesis
and cell division [24, 25]. Kobayashi et al. [23] studied the
expression of PDGF-BB during the early healing of the
supraspinatus tendon in New Zealand white rabbits. They
found that the highest concentration of PDGF-BB occurred
between days 7 and 14. This period coincides with the
terminal part of the inflammatory phase of tendon healing
and the early part of the repair phase.
Several studies have examined the role of PDGF as a
mitogenic and chemotactic cytokine that can enhance tendon
and ligament healing.
Uggen et al. [26] showed restoration of normal crimp
patterning and collagen-bundle alignment in a rat rotator
cuff repair model after delivery of cells expressing PDGF-
BB on a polyglycolic acid scaffold, compared with controls.
Later, the same authors examined the effects of recombinant
human PDGF-BB-coated sutures on rotator cuff healing in
a sheep model [27]. This study showed enhanced histological
scores of the treatment group in comparisonwith controls at a
follow-upperiod of 6weeks; however, therewas no significant
difference between the groups in terms of ultimate load-to-
failure.
A similar study used an interpositional graft composed of
a type I collagen matrix, enriched with recombinant human
PDGF-BB (rhPDGF-BB), implanted in an ovine model for
rotator cuff repair [28]. At 12 weeks after repair, the inter-
positional graft at low and medium dosages of rhPDGF-
BB (75 and 150mg) had improved biomechanical strength
and anatomic appearance compared with the control group
and the 500mg rhPDGF-BB group. These studies highlight
again the importance of PDGF dosing, timing, and delivery
methods. Although the exact answer still remains unclear,
PDGF augmentation holds promise for augmenting tendon-
to-bone healing.
TGF-𝛽 is a family of cytokines that includes three
isoforms (TGF-𝛽1, 2, and 3). Although this superfamily is
responsible for numerous physiologic effects, it is of particu-
lar interest in biological augmentation, as it is thought to play
an important role in tendon and ligament formation through
cellular proliferation, differentiation, and matrix synthesis
[24].
Of the three isoforms, TGF-𝛽3 holds the greatest promise
to enhance the local microenvironment of the rotator cuff
repair site because its high expression during fetal wound
healing correlates with no formation of scar tissue [29].
By contrast, postnatal wound healing is characterized by
extensive scar formation, with high levels of TGF-𝛽1 and
TGF-𝛽2 expression and low level of TGF-𝛽3. Because TGF-
𝛽3 is not present within the adult healing environment, its
exogenous application could promote a scarless regenerative
healing process. Based on this assumption, three recent
studies have specifically examined the use of TGF-𝛽3 in a rat
rotator cuff model [29–31].
Kim et al. [30]. used an osmotic pump delivery system
to specifically investigate the role of TGF-𝛽1 and TGF-𝛽3 at
the tendon-to-bone insertion of repaired rat supraspinatus
tendons. The TGF-𝛽1 group showed increased type III col-
lagen production compared with control shoulders, which
is consistent with a scar-mediated healing response. There
was also a trend toward reduced mechanical properties
within this group. By contrast, the TGF-𝛽3 group showed
no histological or biomechanical differences compared with
the paired controls. While these results support the TGF- 𝛽1
mediated reparative healing response, the lack of improve-
ment in the TGF-𝛽3 group could be attributed to the delivery
system used.
A subsequent study by the same group using a heparin-
/fibrin-based TGF-𝛽3 delivery system to the tendon-to-bone
insertion demonstrated accelerated healing with increased
inflammation, cellularity, vascularity, and cell proliferation
at early time points [29]. In addition, there were significant
improvements in structural andmechanical properties, com-
pared with controls. These findings suggest that TGF-𝛽3 can
enhance tendon-to-bone healing in vivo in a rat model. In
a further study the authors examined the delivery to the
tendon-bone interface of repaired rat supraspinatus tendons
of TGF-𝛽3 in an injectable calcium-phosphate matrix (Ca-P)
[31].The authors found new bone formation, increased fibro-
cartilage, and improved collagen organization with the use of
the osteoconductive Ca-P matrix alone. With the addition of
TGF-𝛽3 to the Ca-P matrix, there was a significant improve-
ment in strength at the repair site 4 weeks postoperatively
and a more favorable collagen type I/III ratio, which reflects
more mature healing. These results further support the role
of TGF-𝛽3 in improving tendon healing after surgical repair;
however, future studies are needed to optimize delivery tech-
niques and dosing as well as to examine the effects of multiple
growth factors administration on the healing process.
3. PRP
The use of PRP as a biological solution to improve rotator
cuff tendon healing has gained popularity over the last several
years.
PRP is a whole blood fraction containing high platelet
concentrations that, once activated, provides a release of
various growth factors which participate in tissue repair proc-
esses [32].
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In vitro studies on the effect of PRP on human tenocytes
from rotator cuff with degenerative lesions showed that
growth factors released by platelets may enhance cell prolifer-
ation of tenocytes and promote the synthesis of extracellular
matrix [33, 34].
PRP not only inhibits the inflammatory effects of inter-
leukin 1𝛽 (IL-1𝛽) but also enhances TGF-𝛽 production.
Increased concentration of IL-1𝛽 is significantly correlated
with rotator cuff tendon degeneration; conversely, TGF-𝛽
enhances rotator cuff tendon repair strength [35]. Further-
more, an in vivo animal study showed that different types of
application did not influence the effect of PRP on rotator cuff
healing [36].
3.1. PRP Formulation. There are several different PRP for-
mulations currently available. PRP can be classified into
four main categories: pure PRP (P-PRP), leucocyte-rich PRP
(L-PRP), pure platelet-rich fibrin (P-PRF), and leucocyte-
rich platelet-rich fibrin (L-PRF). In each category, platelet
concentration can be obtained by different processes, either
in a fully automatized setup or by manual protocols [37].
Among PRP formulations, a further division can bemade
between those which are activated ex vivo with thrombin
and/or calcium and those unactivated, which rely on in vivo
activation via endogenous collagen [38].
The role of leucocytes in PRP is a controversial issue in
the literature.
Basic science studies showed that growth factors and
cytokine concentrations are influenced by the cellular com-
position of PRP, with leukocytes increasing catabolic signal-
ing molecules [39].
Furthermore L-PRP has been found more proinflamma-
tory when injected in rabbits [40] and increased the levels
of MMPs when assayed in tenocyte cultures compared with
pure PRP [41]. However, other studies have pointed out the
positive role of leucocytes in PRP as anti-infectious and
immune regulatory agents [42–45].
Most clinical studies have used numerous different PRP
formulations. The obtained results have never been analyzed
using the leucocyte content of the final concentrate as a
key parameter. Thus, differences between P-PRP and L-PRP
preparations are still unknown.
However the leukocyte content does not seem to induce
negative effects or to impair the potentially beneficial effects
of PRP and no uncontrolled immune reactions of L-PRPs
have been also reported; on the contrary, the use of L-PRP
could diminish pain and inflammation of the treated sites
[46, 47]. Further randomized controlled trials comparing the
effectiveness of L-PRP versus P-PRP will help in defining the
optimal PRP formulation to manage rotator cuff injuries.
3.2. Surgical Use of PRP in Arthroscopic Rotator Cuff Repair.
Literature showed that PRP can be applied either by direct
injection or by application of a PRP matrix scaffold on
repaired tissues. The main characteristics of controlled clin-
ical studies using PRP in arthroscopic rotator cuff repair are
reported in Table 1 [5–18].
Conflicting results on the effectiveness of PRP use in rota-
tor cuff tendon repair were produced, making it now difficult
to draw definitive conclusions.
The clinical studies published to date have different
experimental designs with a level of evidence that varies from
1 to 4. Moreover, there are differences in PRP formulations in
terms of growth factor concentration and catabolic enzyme
content [39]. A PRP classification system exists, which is
based on whether white blood cells are present and whether
PRP is used in an activated (ex vivo activation with thrombin
and/or calcium) or unactivated form (in vivo activation via
endogenous collagen) [48].
Experimental protocols present differences among the
trials, concerning volume of autologous blood collected,
speed and time of centrifugation, method of administration,
activating agent, presence of leukocytes, final volume of PRP,
and final concentration of platelets and growth factors. The
surgical technique (transosseous equivalent, single, or double
row) and the rehabilitation protocol (standard or rapid) were
not the same among different studies.
In spite of the differences in surgical techniques, PRP
formulation, size of the lesions, retear rate have been recal-
culated by combining the available data from studies in order
to determine the role of PRP in improving the rotator cuff
healing after surgical repair.
Differences in term of retear rate between PRP and
control group were assessed by a chi-square test. The analysis
of all studies examined showed that there was no significant
difference in the retear rate between PRP and control group.
The retear rate was 31% (101 out of 323) and 37% (115 out of
312), respectively (𝑃 value > 0.05).
A significant difference was found when a stratified
analysis was performed to analyze the results of small and
medium lesions of the rotator cuff. The rate of reinjury was
7.9% among patients treated with PRP, compared to 26.8% of
those treated without PRP [49].
It is important to emphasize that, with the exception of
two cases of infection, no complications have been reported
from the use of PRP. Bergeson et al. [17] showed an infection
rate of 12% among patients treated with fibrin matrix rich in
platelets without leucocytes compared to 0% in the control
group. However, this difference did not reach statistical
significance, and no difference in the rates of infection or
complication rates was found in the remaining studies.
Although clinical studies have produced conflicting
results, data on PRP suggest a beneficial effect on healing
process when applied during rotator cuff repair.The stratified
analysis of small or medium lesions showed a significantly
lower retear rate in the PRP group. Therefore, it currently
seems that PRP may improve healing of arthroscopically
repaired small andmedium rotator cuff lesions, which appear
more prone to a biological response to treatment with growth
factors.
Further prospective randomized controlled trials (level 1
evidence) are necessary to define the role of PRP in healing
of rotator cuff repair.
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Table 1: Controlled clinical studies investigating the use of PRP in rotator cuff lesions.
Surgical use of PRP in arthroscopic rotator cuff repair
Author Evidence PRP formulation Surgical technique Number ofpatients Comments
Randelli et al.
(2011) [5]
Level 1
Randomized
controlled
Injectable PRP
(GPS system) Single row 53
Better clinical outcomes at 3mo; better
clinical outcomes at 12, 24 months for
smaller tears with PRP
Ruiz-Moneo et al.
(2013) [6]
Level 1
Randomized
controlled
Injectable PRP
(PRGF Endoret
system)
Double row 63 No differences in rotator cuff healing orfunction at 1 year
Antun˜a et al.
(2013) [7]
Level 2
Randomized
controlled
Injectable PRP
(Vivostat system) Single row 28
No differences in clinical outcomes and
healing rate at 2 years
Charousset et al.
(2014) [8]
Level 3
Case control
Injectable PRP
(GPS system) Double row 70
No differences in cuff healing or function
at 2 years
A significant advantage for the L-PRP
patients in terms of smaller iterative tears
Gumina et al.
(2012) [9]
Level 1
Randomized
controlled
Suturable PRP
(RegenKit-THT
system)
Single row 76 Lower retear in the PRP group; nodifferences for clinical outcomes
Jo et al.
(2011) [10]
Level 2
Prospective
cohort
Suturable PRP
(COBE spectra
system)
Transosseous
equivalent 42
Trend for lower re-tearing in the PRP
group; no differences for recovery and
function
Jo et al.
(2013) [11]
Level 1
Randomized
controlled
Suturable PRP
(COBE spectra
system)
Transosseous
equivalent 48
Lower retear and function at 1 year in the
PRP group
Zumstein et al.
(2014) [12]
Level 1
Randomized
controlled
Suturable PRP
(PRF process)
Transosseous
equivalent 20
Increased vascularization for cuff tears
with PRP
Castricini et al.
(2011) [13]
Level 1
Randomized
controlled
Suturable PRP
(Cascade system) Double row 88
No difference for clinical outcomes at 16
months; better restoration of footprint in
PRP group
Lower retear using the chi-square test for
binomial in Arnoczky [14] analysis
Rodeo et al.
(2012) [15]
Level 2
Randomized
controlled
Suturable PRP
(Cascade system)
Single OR double
row/transosseous
equivalent
67 No difference in tendon healing, tendonvascularity, and clinical scores at 1 year
Barber et al.
(2011) [16]
Level 3
Case-control
study
Suturable PRP
(Cascade system) Single row 40
Lower retear in the PRP group; better
healing for smaller tears with PRP
Bergeson et al.
(2012) [17]
Level 3
Cohort study
Suturable PRP
(Cascade system)
Single or double
row 37
Higher retear rate in patients with at-risk
rotator cuff tears with PRFM; no
difference in functional outcome scores
Historical control group
Weber et al.
(2013) [18]
Level 1
Randomized
controlled
Suturable PRP
(Cascade system) Single row 60
No difference in perioperative morbidity,
clinical outcomes, or structural integrity
PRP injections for rotator cuff tendinopathy
Author Evidence PRP intervention Controlintervention
Number of
patients Comments
Rha et al.
(2013) [19]
Level 1
Randomized
controlled
2 PRP (3mL)
injections at a
4-week interval
2 dry needling
procedures at a
4-week interval
39
PRP was superior with respect to pain,
function, and range of motion over a
6-month period
Kesikburun et al.
(2013) [20]
Level 1
Randomized
controlled
1 injection of PRP
(5mL)
1 injection of saline
solution (5mL) 40
No difference for quality of life, pain,
disability, and range of motion at 1 year
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3.3. PRP Injections for Rotator Cuff Tendinopathy. Injections
of PRP have gained popularity in the treatment of tendi-
nopathy because of their promoting effects on tendon cell
proliferation, collagen synthesis, and vascularization, which
have been shown in animal and in vitro studies [34, 50].
In spite of this popularity and increasing use in clinical
settings we have found only two controlled randomized
trials evaluating the use of PRP injections in rotator cuff
tendinopathy [19, 20].
These studies have reported controversial results on the
effectiveness of the use of PRP injection in chronic rotator
cuff tendon diseases.
The systems of PRP preparationwere not the same among
trials and different treatment protocols were used (single or
double PRP injections). Furthermore, the presence of some
bias including the concomitant standard exercise program
and the needle stimulus effect can have influenced the results
of studies. The nature of rotator cuff disease was also not
the same throughout the studies and patients refractory to
physical therapy and corticosteroid injection seem to have a
benefit from the PRP use.
Extrinsic and intrinsic factors including anatomical prob-
lems, joint kinematics alterations, and age- and vascularity-
related degenerative changes may play a role in developing
such disease.
More studies with a high level of evidence are required to
validate the role of PRP injections in the subacromial space
for treatment of rotator cuff diseases.
4. Stem Cells
4.1. Definition. Stem cells are defined as unspecialized cells
with a self-renewal potential, which are able to differentiate
into various adult cell types. The most common stem cell
sources are embryonic and adult stem cells.
Embryonic stem cells are truly pluripotent; that is, they
are able to differentiate into all derivatives of the three
primary germ layers: ectoderm, endoderm, and mesoderm.
In contrast to embryonic stem cells, multipotent adult
stem cells are characterized by a differentiation potential
restricted to tissues of 1 germ layer. Those which can differ-
entiate into various forms of mesenchymal tissue (i.e., bone,
tendon, cartilage, andmuscle) are termedmesenchymal stem
cells (MSCs).
Most of the clinical related stem cells research to date
has focused on adult stem cells rather than embryonic stem
cells, as the latter are associated with numerous regulatory
and ethical constraints.
4.2. Mesenchymal Stem Cells. MSCs are progenitor cells that
have the capacity to self-renew and differentiate into several
different mesenchymal tissues including muscle, fat, bone,
ligament, tendon, and cartilage [51]. For this reason, MSCs
can theoretically be stimulated to undergo differentiation to
a preferred lineage (osteocytes, chondrocytes, tenocytes, and
adipocytes), thus recreating a specific tissue for therapeutic
use [51].
4.3. Source of MSCs. Bone marrow is the main source of
MSCs for rotator cuff healing and can be easily accessed
by surgeons to harvest cells, the extraction and culture
techniques of which, as well as the conditions for propaga-
tion, have been extensively defined. For these reasons, bone
marrow-derived MSCs (BMSCs) may have valid clinical use,
and there is evidence showing that BMSCs can be manip-
ulated to differentiate into a tenogenic lineage and produce
tendon tissue when exposed to the appropriate stimuli.
The iliac crest is the most common site for MSC harvest-
ing, although a number of other sources have been recently
identified. Recent research performed by Mazzocca et al.
[52] demonstrated that MSCs can be successfully and safely
harvested from the proximal humerus during arthroscopic
rotator cuff repair in humans and thus potentially applied to
the repair site of the same patient to augment tendon-to-bone
healing. In another study, authors characterized the harvested
cells as BMSCs and induced differentiation in tenocyte-like
cells by treatmentwith insulin [53].This grouphas shown that
it is possible to extract culture and differentiate stem cells into
tendon cells in humans.
Beitzel et al. [54, 55] showed that arthroscopic bone mar-
row aspiration from the proximal humerus is a reproducible
technique and yields reliable concentrations of MSCs. These
studies demonstrate that BMSCs can be harvested avoiding
an additional surgical site for aspiration (i.e., iliac crest) or a
second operative procedure, making future use of MSCs in
arthroscopic rotator cuff surgery easy.
MSCs can also be collected from other sources, such as
adipose tissue; this can be easily accessible although its cells
have an apparently reduced ability to differentiate compared
to BMSCs [56].
Tendon derived stem cells (TDSCs) are considered of
extreme interest for rotator cuff repair enhancement. Exis-
tence of TDSCs has been first shown in murine patellar and
human hamstring tendons by Bi et al. [57]. More recent ex
vivo studies confirmed TDSCs isolation from animal and
human rotator cuff tissues. Tsai et al. [58] showed on 5
patients that cells harvested from the rotator cuff tendon
could be successfully isolated and differentiated into cells
with MSCs characteristics. In 2013, Randelli et al. [59]
confirmed the existence of new stem cell populations in
shoulder tissues; samples from human supraspinatus tendon
and human long head of the biceps tendon were collected
during arthroscopic rotator cuff repairs from 26 patients.
Morphology, self-renewal capacity, immunophenotype, gene
and protein expression profiles, and differentiation capacity
were evaluated and resulted in characterization of two new
types of human stem cells. In the same year, Utsunomiya et
al. [60] isolated and characterized MSCs from four shoul-
der tissues: synovium of glenohumeral joint, subacromial
bursa, rotator cuff tendon, and enthesis at greater tuberosity,
obtained from shoulder joint of 19 patients undergoing
arthroscopic rotator cuff repair, suggesting that subacromial
bursa is a good candidate for the source of MSCs in rotator
cuff tears.
Recently, Song et al. [61] isolated MSCs from bursa
tissue associated with rotator cuff tendons from five patients
undergoing rotator cuff surgery and characterized them for
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multilineage differentiation in vitro and in vivo. These results
showed in animal models that the cells isolated from bursa
tissue exhibited MSCs characteristics and high proliferative
capacity, and differentiated toward cells of mesenchymal
lineages (osteoblasts, tenocytes, and fibrochondrocytes) with
high efficiency suggesting that bursa, a tissue usually dis-
carded during rotator cuff tear repairs, is a new abundant
source of MSCs with a high potential for application.
4.4. Animal Studies. The use of MSCs to enhance tendon
regeneration has been examined in multiple animal models
of tendon healing. MSC can be applied directly to the site
of injury or can be delivered on a suitable carrier matrix,
which functions as a scaffold while tissue repair takes place.
In an attempt to augment tendon-bone healing in a rat rotator
cuff repair model, Gulotta et al. [62] in 2009 conducted
a case-control study on 80 rats that underwent unilateral
detachment and repair of the supraspinatus tendon. BMSCs
obtained from long bones of 10 rats were applied to the
repair site. No significant differences were observed with
the control group, in which the rotator cuff repair was not
followed by stem cells injection. Authors concluded that
MSCs alone are not sufficient to improve tendon-to-bone
healing in a rotator cuff model as the repair site may lack the
cellular and/or molecular signals needed to induce appropri-
ate differentiation of the transplanted cells, suggesting that
additional differentiation factors may need to be combined
with this cell-based therapy to be effective. Knowledge of the
biological signaling events that lead to the formation of the
natural enthesis suggests candidate molecules that could be
used in combination with MSCs to augment the repair site.
Therefore, in later studies, Gulotta et al. [63, 64] examined
various types of transducedMSCs with the aim of driving the
healing process toward regeneration rather than repair of the
tendon-bone structure. Three controlled laboratory studies
showed that transducing cells with scleraxis or membrane
type 1matrixmetalloproteinase improved histological quality
and biomechanical strength as early as 4 weeks after repair,
whereas transducing the cells with BMP-13 did not achieve
favorable results.
Yokoya et al. [65] studied the implantation of a polyg-
lycolic acid sheet seeded with cultured autologous BMSCs
in a complete infraspinatus lesion created in a rabbit model.
Sixteenweeks after the implantation, an increased production
of type I collagen and an increment of the mechanical
strength was seen as compared with both a nonaugmented
control and a nonloaded scaffold group.
Kim et al. [66] harvested BMSCs from the iliac crest of
2 rabbits and cultured and seeded them on a tridimensional
open-cell polylactic acid scaffold. A similar scaffold without
stem cells was implanted on the contralateral shoulder as
control.This study showed that BMSCs survived for 2, 4, and
6 weeks within the scaffold and type I collagen expression
was increased in the scaffold with BMSCs as compared with
control.
Shen et al. [67] used a knitted silk-collagen scaffold,
loaded with allogenous Achilles tendon stem cells, to aug-
ment a rotator cuff repair in rabbits, and compared these
with repairs augmented with a nonloaded scaffold. No
reject reactions were observed and increased fibroblastic cell
ingrowth and reduced infiltration of lymphocytes within the
implantation site were observed in the treatment group after
4 and 8 weeks. Morphological evaluation performed after 12
weeks showed an improvement in structural and mechanical
proprieties, as compared with control.
4.5. Clinical Studies. Up to now, only one cohort study
has evaluated the safety of clinical application of MSCs in
shoulder surgery. In this study Gomes et al. [68] investigated
the effects of bone marrow mononuclear cells (BMMCs) in
14 patients with complete rotator cuff tears, suggesting that
BMMCs are a safe and promising alternative to other biolog-
ical approaches to enhance tissue quality in affected tendons.
Autologous BMMCs were harvested from the iliac crest
prior to the surgical repair and subsequently injected into ten-
don borders after being fixed down by transosseous stitches.
The BMMC fractions were obtained by cell sorting and
resuspended in saline enriched with 10% autologous serum.
Each patient was monitored for a minimum of 12 months,
and University of California, Los Angeles (UCLA), scores
improved on average from 12 to 31, and magnetic resonance
imaging showed tendon integrity in all 14 patients. No control
group was included in this study, but for this procedure,
overall rates of rerupture during the first postoperative year
range from 25% to 65%, depending on lesion diameter. Only
1 patient in the following year relapsed with loss of strength
and pain. Unfortunately, only 14 patients were enrolled in
this study, making it difficult to determine the efficacy of
BMMCs as an adjunct to cuff repair at this time. However,
these results suggest that BMMC therapy is a safe treatment
that has potential to enhance tendon repair. Further research
will be critical to better investigate the use of this biologic
approach.
5. Conclusions
Several regenerative approaches have been investigated to
augment tendon healing after arthroscopic cuff repair.
The ability of numerous growth factors to affect tendon
healing has been extensively analyzed in vitro and in animal
models, showing promising results. However there is still no
study on the use of growth factors in the treatment of rotator
cuff on human.
Different delivery systems for these factors, including
simple injection, coated sutures, fibrin sealants, heparin-
fibrin delivery systems, collagen, and hyaluronic acid
sponges, are being tested. PRP is awhole blood fractionwhich
contains several growth factors. Different PRP formulations
exist: leucocyte-poor and leucocyte-rich, activated and unac-
tivated. Moreover, PRP can be administrated either with
a simple injection or in a fibrin-matrix clot. Clinical trials
using different autologous PRP formulations after rotator
cuff tear repairs have provided controversial results.
However, favourable structural healing rates have been
observed for surgical repair of small andmedium rotator cuff
tears.
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Cell-based approaches have also been suggested to
enhance tendon healing. Bone marrow is a well known
source ofMSCs; recently, ex vivo human studies have isolated
and cultured distinct populations of MSCs from rotator
cuff tendons, long head of the biceps tendon, subacromial
bursa, and glenohumeral synovia. A single clinical study has
been conducted on stem cell-based therapies for rotator cuff
healing, proving the injection of bone marrow mononuclear
cells to be safe. Clinical research regarding the use of MSCs
in shoulder surgery is very limited. Further basic and clinical
investigations are required until a procedure can be defined
for the routine use of these cells in shoulder surgery.
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